ClinicalTrials.gg
CompletedNCT02727907Updated Feb 17, 2023Results posted

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

A Phase 2/3 interventional study of BCD-033 (interferon beta 1a) and Rebif (interferon beta 1a) in Multiple Sclerosis, sponsored by Biocad. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-02-17.

Sponsored by Biocad · Phase 2/3, Interventional, and Other

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2015, registered May 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.

Enrollment
9th of 34
163 · median 85
Started
2015
the only one that year
Phase 2/3
Only one
of the 34
Registered
34th of 34
by date
Lead sponsor
1 of 34
Biocad

Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 9th largest by enrollment, is the only one that started in 2015, is the only one in phase 2/3, and was the 34th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing Interferon beta-1a in Multiple Sclerosis as a file.
02

Study summary

Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with the use of active comparator and placebo. Total duration of therapy of about 2 years. Study hypothesis is equivalence of efficacy and safety of the investigational drug BCD-033 original drug Rebif®.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-55
  2. Patients of both genders with Multiple Sclerosis (McDonald criteria 2010)
  3. No relapses 28 days before randomisation
  4. Expanded Disability Status Scale score 0-5,5

Exclusion criteria

Exclusion Criteria

  1. Primary or secondary progression of Multiple Sclerosis
  2. Expanded Disability Status Scale score more then 5,5
  3. Severe depression, suicide ideas and/or attempts
  4. Systemic application in 30 days before randomisation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    BCD-033

    Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks

    Drug: BCD-033 (interferon beta 1a)

  • Active comparator
    Rebif

    Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks, followed by 48 weeks of open-label BCD-033 usage

    Drug: Rebif (interferon beta 1a)

  • Placebo comparator
    Placebo

    Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for 48 weeks, followed by 72 weeks of open-label BCD-033 usage

    Drug: Placebo

Interventions

  • Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks

  • Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks

  • DrugPlacebo

    Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks

06

What researchers measure

Primary outcomes

  1. Number of Combined Unique Active Lesions

    Number of Combined Unique Active Lesions (CUA) -- the number of new MRI contrast uptake lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice) after 52 weeks blinded application of interferon-β1а (BCD-033 and Rebif®) (44 mcg).

    Time frame: 52 weeks

Secondary outcomes

  1. Annual Relapse Rate

    Annual relapse rate ARR for 52 weeks was evaluated in all three groups, after the application of IFN beta-1a

    Time frame: 52 weeks

  2. Proportion of Subjects Without Confirmed Relapse

    proportion of subjects without confirmed relapse in PP

    Time frame: 16, 52 weeks

  3. Relapse Free Time

    Time to first relapse in "per protocol" population

    Time frame: 96 weeks

  4. Number of Combined Unique Active Lesions

    CUA (the number of new contrast-enhanced lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice)

    Time frame: 96 weeks

  5. Annual Relapse Rate

    Annual Relapse Rate ARR for 96 weeks was evaluated in two groups, after the administraion of IFN beta-1a in a full dose for 96 weeks.

    Time frame: 96 week

  6. Relapse Free Time

    Time to first relapse in "per protocol" population

    Time frame: 16, 52 weeks

  7. Number of Combined Unique Active Lesions

    CUA (the number of new contrast-enhanced lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice).

    Time frame: 16 weeks

Other outcomes

  1. Adverse Events/Serious Adverse Events

    quantity and grade of all AE/SAE is calculated in subjects, who received at least one dose of study drug

    Time frame: 96 weeks

  2. Severe Adverse Events Frequency

    AE grade 3-4 (CTCAE 4.03) is calculated in subjects, who received at least one dose of study drug

    Time frame: 52 weeks

  3. Withdrawal

    quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug

    Time frame: 16, 52 weeks

  4. Immunogenicity

    Count of Participants with Binding and Neutralizing Antibodies

    Time frame: 16, 52 weeks

  5. Adverse Reaction/Serious Adverse Reactions

    quantity and grade of all adverse reactions/serious adverse reactions is calculated in subjects, who received at least one dose of study drug

    Time frame: 16, 52 weeks

  6. Severe Adverse Events Frequency

    AE grade 3-4 (CTCAE 4.03)is calculated in subjects, who received at least one dose of study drug

    Time frame: 96 weeks

  7. Withdrawal

    quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug

    Time frame: 96 weeks

  8. Immunogenicity

    Count of Participants with Binding and Neutralizing Antibodies

    Time frame: 96 weeks

  9. Serious Adverse Events

    quantity and grade of all SAE is calculated in subjects, who received at least one dose of study drug

    Time frame: 52 week of study

07

Results

Posted Feb 17, 2023

Participant flow

Participant flow — Overall Study
MilestoneBCD-033Rebif/BCD-033Placebo/BCD-033
Started535654
Recived one injection of drug535554
Completed404343
Not completed131311

Outcome measures

PrimaryNumber of Combined Unique Active Lesions

Number of Combined Unique Active Lesions (CUA) -- the number of new MRI contrast uptake lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice) after 52 weeks blinded application of interferon-β1а (BCD-033 and Rebif®) (44 mcg).

Time frame:
52 weeks
Reported as:
Median · lesions
Number of Combined Unique Active Lesions
lesionsBCD-033Rebif
Number of Combined Unique Active Lesions0.0 (0.0 to 1.25)0.0 (0.0 to 1.0)
SecondaryAnnual Relapse Rate

Annual relapse rate ARR for 52 weeks was evaluated in all three groups, after the application of IFN beta-1a

Time frame:
52 weeks
Reported as:
Mean · relapses
Annual Relapse Rate
relapsesBCD-033Rebif / BCD-033Placebo / BCD-033
Annual Relapse Rate0.113 ± 0.3750.091 ± 0.3480.109 ± 0.369
SecondaryProportion of Subjects Without Confirmed Relapse

proportion of subjects without confirmed relapse in PP

Time frame:
16, 52 weeks
Reported as:
Number · Count of Participants
Proportion of Subjects Without Confirmed Relapse
Count of ParticipantsBCD-033RebifPlacebo
week 16494645
week 52414439
SecondaryRelapse Free Time

Time to first relapse in "per protocol" population

Time frame:
96 weeks
Reported as:
Median · days
Relapse Free Time
daysBCD-033Rebif/BCD-033
Relapse Free Time207.0 (52.0 to 276.0)183.0 (26.0 to 286.0)
SecondaryNumber of Combined Unique Active Lesions

CUA (the number of new contrast-enhanced lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice)

Time frame:
96 weeks
Reported as:
Median · lesions
Number of Combined Unique Active Lesions
lesionsBCD-033Rebif/BCD-033
Number of Combined Unique Active Lesions0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)
SecondaryAnnual Relapse Rate

Annual Relapse Rate ARR for 96 weeks was evaluated in two groups, after the administraion of IFN beta-1a in a full dose for 96 weeks.

Time frame:
96 week
Reported as:
Mean · relapses
Annual Relapse Rate
relapsesBCD-033Rebif
Annual Relapse Rate0.208 ± 0.5320.145 ± 0.524
SecondaryRelapse Free Time

Time to first relapse in "per protocol" population

Time frame:
16, 52 weeks
Reported as:
Median · days
Relapse Free Time
daysBCD-033RebifPlacebo/BCD-033
week 1633.5 (12.0 to 60.0)14.0 (12 to 26.0)15.0 (5.0 to 61.75)
week 52193.0 (51.5 to 240.0)123.5 (22.5 to 204.75)74.0 (25.0 to 210.0)
SecondaryNumber of Combined Unique Active Lesions

CUA (the number of new contrast-enhanced lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice).

Time frame:
16 weeks
Reported as:
Median · lesions
Number of Combined Unique Active Lesions
lesionsBCD-033RebifPlacebo
Number of Combined Unique Active Lesions0.0 (0.0 to 2.0)0.0 (0.0 to 1.0)1.0 (0.0 to 3.0)
Other pre-specifiedAdverse Events/Serious Adverse Events

quantity and grade of all AE/SAE is calculated in subjects, who received at least one dose of study drug

Time frame:
96 weeks
Reported as:
Number · adverse events
Adverse Events/Serious Adverse Events
adverse eventsBCD-033Rebif/BCD-033
Adverse Events/Serious Adverse Events124110
Other pre-specifiedSevere Adverse Events Frequency

AE grade 3-4 (CTCAE 4.03) is calculated in subjects, who received at least one dose of study drug

Time frame:
52 weeks
Reported as:
Number · adverse events
Severe Adverse Events Frequency
adverse eventsBCD-033RebifPlacebo/BCD-033
Severe Adverse Events Frequency547
Other pre-specifiedWithdrawal

quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug

Time frame:
16, 52 weeks
Reported as:
Count of participants · Participants
Withdrawal
ParticipantsBCD-033RebifPlacebo/BCD-033
week 16011
week 52112
Other pre-specifiedImmunogenicity

Count of Participants with Binding and Neutralizing Antibodies

Time frame:
16, 52 weeks
Reported as:
Number · participants
Immunogenicity
participantsBCD-033Rebif/BCD-033Placebo/BCD-033
week 16 : Binding Antibodies652
week 16 : Neutralizing Antibodies552
week 52 : Binding Antibodies1097
week 52 : Neutralizing Antibodies987
Other pre-specifiedAdverse Reaction/Serious Adverse Reactions

quantity and grade of all adverse reactions/serious adverse reactions is calculated in subjects, who received at least one dose of study drug

Time frame:
16, 52 weeks
Reported as:
Number · adverse events
Adverse Reaction/Serious Adverse Reactions
adverse eventsBCD-033RebifPlacebo/BCD-033
week 16675933
week 52928092
Other pre-specifiedSevere Adverse Events Frequency

AE grade 3-4 (CTCAE 4.03)is calculated in subjects, who received at least one dose of study drug

Time frame:
96 weeks
Reported as:
Number · adverse events
Severe Adverse Events Frequency
adverse eventsBCD-033Rebif/BCD-033
Severe Adverse Events Frequency23
Other pre-specifiedWithdrawal

quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug

Time frame:
96 weeks
Reported as:
Count of participants · Participants
Withdrawal
ParticipantsBCD-033Rebif/BCD-033
Withdrawal11
Other pre-specifiedImmunogenicity

Count of Participants with Binding and Neutralizing Antibodies

Time frame:
96 weeks
Reported as:
Number · participants
Immunogenicity
participantsBCD-033Rebif/BCD-033
Binding Antibodies1914
Neutralizing Antibodies1613
Other pre-specifiedSerious Adverse Events

quantity and grade of all SAE is calculated in subjects, who received at least one dose of study drug

Time frame:
52 week of study
Reported as:
Number · adverse events
Serious Adverse Events
adverse eventsBCD-033Rebif/BCD-033Placebo/BCD-033
Serious Adverse Events003

Adverse events

Collected over 52 week. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCD-0330/53 (0%)0/53 (0%)35/53 (66%)
Rebif0/55 (0%)0/55 (0%)32/55 (58.2%)
Placebo/BCD-0330/54 (0%)2/54 (3.7%)34/54 (63%)
Most frequent serious events
Most frequent serious events
EventBCD-033RebifPlacebo/BCD-033
nephrotic syndromeRenal and urinary disorders0/530/551/54
Left hemophthalmosEye disorders——1/54
Chronic viral hepatitis BInfections and infestations——1/54
Most frequent other events
Most frequent other events
EventBCD-033RebifPlacebo/BCD-033
flu-like syndromGeneral disorders15/5316/5519/54
local reactionGeneral disorders15/5312/5510/54
neutropeniaInvestigations11/534/5510/54
feverGeneral disorders7/536/556/54
lymphopeniaInvestigations5/534/554/54
thrombocytopeniaInvestigations3/535/553/54
increased ALTInvestigations3/534/553/54
headacheGeneral disorders3/533/553/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BCD-033Rebif / BCD-033Placebo / BCD-033Total
<=18 years0000
Between 18 and 65 years535554162
>=65 years0000
Age, Continuous
Age, Continuous(years)BCD-033Rebif / BCD-033Placebo / BCD-033Total
Median28.00 (25.00 to 39.0)30.00 (26.0 to 37.0)29.5 (26.0 to 38.0)29.0 (26.0 to 38.0)
Sex: Female, Male
Sex: Female, Male(Participants)BCD-033Rebif / BCD-033Placebo / BCD-033Total
Female383134103
Male15242059
08

Study locations

1 site
  • Scientific neurology center, RAS
    Moscow, Russian Federation
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Nov 2016, 21 months.

Results were first posted in Feb 2023, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2015
First posted
Apr 5, 2016
StartActual
Feb 12, 2015
Primary completionActual
Nov 21, 2016
CompletionActual
Aug 11, 2017
Results first posted
Feb 17, 2023
Last update
Feb 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02727907
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Apr 5, 2016
Start date
Feb 12, 2015
Primary completion
Nov 21, 2016
Completion
Aug 11, 2017
Results posted
Feb 17, 2023
Last update
Feb 17, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion